Search
Selected Filter
Displaying 251–260 of 541 news results
-
ProQR’s RNA Therapy for USH2A Performs Well in Phase 1/2 Clinical Trial
Research NewsThe company is planning two Phase 2/3 clinical trials for the treatment
-
Foundation Fighting Blindness Launches Chapter Program Rebrand
Foundation NewsThe program honors Lulie Gund and her legacy and commitment to the Foundation’s Chapter community.
-
Foundation’s No-Cost Program Increased Genetic Testing Rates for IRD Patients
Research NewsMore than 8,000 people have applied for genetic testing through the Foundation’s program
-
Foundation News
Course Title: Clinical Trials of Emerging Therapies for Retinal Degeneration Patients: Hope and Opportunities
-
A Eureka Moment for Paul Yang Boosts Advancement of Vision-Saving RP Drug
Research NewsHis latest Foundation grant is helping move the drug toward a clinical trial
-
Are You on the Clinical Trial Radar Screen?
Research NewsTherapy developers use the My Retina Tracker Registry to recruit for human studies of emerging therapies
-
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
In the PressFormer Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision’s proprietary asset, SPVN06, and further pipeline development
-
Very-Long-Chain Polyunsaturated Fatty Acids Improve Vision in Mice with a Form of Stargardt Disease
Research NewsResearchers believe the VLC-PUFAs may benefit people with autosomal dominant Stargardt disease, AMD, and possibly other retinal degenerations
-
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
In the PressDevelopment of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board
-
Research News
The company plans to enroll additional patients as young as four years old
